Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumason in pediatric echocardiography
NCT02282163Phase 3Terminated
- Sponsor
- Bracco Diagnostics Inc.
- Start
- Oct 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sulfur hexafluoride in heart disease, sponsored by Bracco Diagnostics Inc. Primary endpoints: Change From Baseline in Total Left Ventricular Endocardial Border Delineation (LV EBD) Scores at Day 1 and Percentage of Participants With Adequate Left Ventricular Opacification (LVO) at Day 1. Started Oct 2015; status: terminated.
02
Drugs
sulfur hexafluoride
03
Conditions
heart disease
Beyond the preview
Go deeper on NCT02282163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282163.